In the brain of mice, 3-iodothyronamine (T1AM) is converted into 3-iodothyroacetic acid (TA1) and it is included within the signaling network connecting thyroid hormone metabolites with histamine

European Journal of Pharmacology

Volumn 761, Issue , 2015, Pages 130-134

  Laurino, Annunziatina ^a   De Siena, Gaetano ^a   Saba, Alessandro ^b   Chiellini, Grazia ^b   Landucci, Elisa ^a   Zucchi, Riccardo ^b   Raimondi, Laura ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

3 iodothyroacetic acid; 3 iodothyronamine; Histamine; Thyroid metabolites

Indexed keywords

3 IODOTHYRONAMIN; 3 IODOTYHYROACETICACID; CLORGYLINE; HISTIDINE DECARBOXYLASE; MEPYRAMINE; THYROID HORMONE; UNCLASSIFIED DRUG; ZOLANTIDINE; 3-IODOTHYROACETIC ACID; 3-IODOTHYRONAMINE; ANTIHISTAMINIC AGENT; HISTAMINE; MONOAMINE OXIDASE INHIBITOR; THYRONINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; HIPPOCAMPUS; HOT PLATE TEST; HYPERALGESIA; LEARNING; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN DEGRADATION; STIMULUS RESPONSE; TASK PERFORMANCE; 129 MOUSE; ANIMAL; ANIMAL BEHAVIOR; AVOIDANCE BEHAVIOR; BIOTRANSFORMATION; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BIOTRANSFORMATION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HISTAMINE; HISTAMINE ANTAGONISTS; HISTIDINE DECARBOXYLASE; HYPERALGESIA; INJECTIONS, INTRAVENTRICULAR; MALE; MICE, 129 STRAIN; MICE, KNOCKOUT; MONOAMINE OXIDASE INHIBITORS; OXIDATION-REDUCTION; PAIN THRESHOLD; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; THYROID HORMONES; THYRONINES;

EID: 84929380276     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.04.038     Document Type: Article

References (25)

1. C. Anaclet, R. Parmentier, K. Ouk, G. Guidon, C. Buda, and J.P. Sastre Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models J. Neurosci. 29 2009 14423 14438
2. G. Chiellini, P. Erba, V. Carnicelli, C. Manfredi, S. Frascarelli, S. Ghelardoni, G. Mariani, and R. Zucchi Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors J. Endocrinol. 213 2012 223 230
3. E. Galli, M. Marchini, A. Saba, S. Berti, M. Tonacchera, P. Vitti, T.S. Scanlan, G. Iervasi, and R. Zucchi Detection of 3-iodothyronamine in human patients: a preliminary study J. Clin. Endocrinol. Metab. 97 2012 E69 E74
4. S.A. Hackenmueller, and T.S. Scanlan Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography tandem mass spectrometry J. Chromatogr.: A 1256 2012 89 97
5. T.J. Haley, and M.C. Cormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse Br. J. Pharmacol. Chemother. 12 1957 12 15
6. A.G. Ianculescu, K.M. Giacomini, and T.S. Scanlan Identification and characterization of 3-iodothyronamine intracellular transport Endocrinology 150 2009 1991 1999
7. M.E. Jarvik, and R. Kopp An improved one-trial passive avoidance learning situation Psychol. Rep. 21 1967 221 224
8. N. Khajavi, P.S. Reinach, N. Slavi, M. Skrzypski, A. Lucius, O. Strauß, J. Köhrle, and S. Mergler Thyronamine induces TRPM8 channel activation in human conjunctival epithelial cells Cell Signal. 27 2014 315 325
9. C. Kilkenny, W. Browne, I.C. Cuthill, M. Emerson, and D.G. Altman Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research J. Pharmacol. Pharmacother. 1 2 2010 94 99 10.4103/0976-500X.72351
10. A. Laurino, G. De Siena, F. Resta, A. Masi, C. Musilli, R. Zucchi, and L. Raimondi 3-iodothyroacetic acid, a metabolite of thyroid hormone, induces itch and reduces threshold to noxious and to painful heat stimuli in mice Br. J. Pharmacol. 172 2015 1859 1868 10.1111/bph.13032 Epub ahead of print
11. M.E. Manni, G. De Siena, A. Saba, M. Marchini, E. Bigagli, and L. Cinci 3-iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in Br J. Pharmacol. 166 2012 650 658
12. M.E. Manni, E. Bigagli, M. Lodovici, M. Zazzeri, and L. Raimondi The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity Pharmacol. Res. 65 2012 465 471
13. M.E. Manni, G. De Siena, A. Saba, M. Marchini, E. Landucci, E. Gerace, M. Zazzeri, C. Musilli, D. Pellegrini-Giampietro, R. Matucci, R. Zucchi, and L. Raimondi Pharmacological effects of 3-iodothyronamine (T1AM) in mic.shold Br. J. Pharmacol. 168 2013 354 362
14. J. McGrath, G. Drummond, E. McLachlan, C. Kilkenny, and C. Wainwright Guidelines for reporting experiments involving animals: the ARRIVE guidelines Br. J. Pharmacol. 160 2010 1573 1576
15. C. Musilli, G. De Siena, M.E. Mann,i, A. Logli, E. Landucci, R. Zucchi, A. Saba, R. Donzelli, M.B. Passani, G. Provensi, and L. Raimondi Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism Br. J. Pharmacol. 171 2014 3476 3484
16. H. Ohtsu, S. Tanaka, T. Terui, Y. Hori, Makabe-Kobayashi, and Y. Pejler Mice lacking histidine decarboxylase exhibit abnormal mast cells FEBS Lett. 502 2001 53 56
17. H.N. Panas, L.J. Lynch, E.J. Vallender, Z. Xie, G.L. Chen, and S.K. Lynn Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice J. Neurosci. Res. 88 2010 1962 1969
18. D.E. Pellegrini-Giampietro, A. Cozzi, F. Peruginelli, E. Meli, R. Pellicciari, and F. Moroni I-Aminoindan-1,4-dicarboxylic acid and (S)-(+)-2-83′-carboxybicyclo [1.1.1]pentyl)-glycine, twomGlu1 receptor-preferring antagonist, reduce neuronal death in vitro and in vivo models of cerebral ischemia Eur. J. Neurosci. 11 1999 3637 3647
19. S. Piehl, C.S. Hoefig, T.S. Scanlan, and J. Köhrle Thyronamines - past, present, and future Endocr. Rev. 32 2011 64 80
20. C.A. Pietsch, T.S. Scanlan, and R.J. Anderson Thyronamines are substrates for human liver sulfotransferases Endocrinology 148 2007 1921 1927
21. R. Pino, P. Failli, L. Mazzetti, and F. Buffoni Monoamine oxidase and S.E.M.icarbazide-sensitive amine oxidase activities in isolated cardiomyocytes of spontaneously hypertensive rats Biochem. Mol. Med. 62 1997 188 196
22. J.B. Regard, H. Kataoka, D.A. Cano, E. Camerer, L. Yin, Y.W. Zheng, T.S. Scanlan, M. Hebrok, and S.R. Coughlin Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion J. Clin. Investig. 117 2007 4034 4043
23. A. Saba, G. Chiellini, S. Frascarelli, M. Marchini, S. Ghelardoni, and A. Raffaelli Tissue distribution and cardiac metabolism of 3-iodothyronamine Endocrinology 151 2010 5063 5073
24. T.S. Scanlan, K.L. Suchland, M.,E. Hart, G. Chiellini, Y. Huang, P.J. Kruzich, S. Frascarelli, D.A. Crossley, J.R. Bunzow, S. Ronca-Testoni, E.T. Lin, D. Hatton, R. Zucchi, and D.K. Grandy 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone Nat. Med. 10 2004 638 642
25. R. Zucchi, A. Accorroni, and G. Chiellini Update on 3-iodothyronamine and its neurological and metabolic actions Front. Physiol. 5 2014 402 10.3389/fphys.2014.00402